CPHI 2025: Redefining Nutraceuticals with New Delivery Formats and Pharma-Grade Standards
The lines between pharmaceuticals and nutraceuticals are becoming increasingly blurred. At this year’s CPHI 2025 trade show, key innovations were showcased, highlighting how efficacy and formats are converging across the two industries.
Industry Convergence and New Delivery Formats
Nutrition Insight engaged with several companies at the event, including PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica, to discuss emerging industry trends. A major focus was on how pharmaceutical standards are influencing the supplement sector.
“They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”
— Matevž Ambrožič, Marketing Director at PharmaLinea
PharmaLinea’s Focus on Clinical Substantiation
PharmaLinea is advancing clinical validation as a crucial step toward producing pharmaceutical-grade supplements. According to Matevž Ambrožič:
“While branded ingredients are increasingly backed by clinical studies, finished-product clinical validation is still rare — and that’s where we focus.”
“We already have several product lines clinically studied at the finished-product level, and a large pipeline of upcoming trials. Our goal is to have our entire portfolio clinically substantiated.”
“That’s our way of adapting to the future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”
The push toward higher quality and clinically verified products underscores an ongoing shift in how nutraceuticals are developed and perceived, aiming to meet elevated pharmaceutical criteria.
Author’s summary: CPHI 2025 demonstrated the increasing integration of pharmaceutical rigor into nutraceuticals, focusing on clinical evidence and innovative delivery methods to raise industry standards.